#SEMSS2023 is off and running, with a great keynote from @LiottaLab, heading into breakout sessions and posters this afternoon! Thanks to the @SEmdphd organizing committees for a great start to the weekend!
.@BayhDole American Innovator Award recipient and @EmoryUniversity professor Dr. @LiottaLab, best known for his groundbreaking discoveries in HIV treatment, was featured in an article by #eGreenews! Read it here ⤵️
https://t.co/7mW17woP0N
Congrats to #EmoryCFAR Member, Dennis Liotta (@LiottaLab) who was honored at the White House for innovation in #HIV treatment! Dr. Liotta was one of five to receive an inaugural @BayhDole American Innovator Award. Learn more via @EmoryNews: https://t.co/C6sSr0i4z3
Nucleoside- and nucleotide-based therapies including Tenofovir (TFV) are commonly given to patients as prodrugs to maximize bioavailability. We designed three series of novel TFV prodrugs shown to optimize antiviral activity and metabolic stability: https://t.co/GJhIm11jkK
A series of NMDA receptor subunit 2B-selective inhibitors show enhanced activity at a more acidic extracellular pH relative to physiologic pH. This property renders compounds more effective at synapses responding to a high frequency of action potentials. https://t.co/HIRwUV9FAS
CXCR4 antagonist TIQ15 was rationally modified to improve drug-like properties. Introducing a nitrogen atom in the tetrahydroisoquinoline ring reduces inhibition of the CYP2D6 enzyme while retaining CXCR4 potency.
https://t.co/oHd0KUApfI
TFV is the cornerstone NtRTI in many combination antiretroviral therapies prescribed to patients living with HIV. This paper describes two novel TFV prodrugs with improved metabolic stability, half-life, and pharmacokinetic traits: https://t.co/HRby6m1znN
.@GC_CUNY alumnus @LiottaLab's innovations have resulted in 18 life-saving FDA-approved antiviral therapeutics, including the first-ever combination therapy for HIV/AIDS as a once-daily pill. Tune into his talk on Oct. 28 to learn all about his research! https://t.co/MavpYTuLYU
Join us in welcoming @GC_CUNY alumnus and Samuel Candler Dobbs Professor of Chemistry @LiottaLab, on Oct. 28 for a talk about novel therapeutics for treating cancers, neurological disorders and viral diseases. @GCsciences https://t.co/1fTvigduY9
Samuel Candler Dobbs Professor of Chemistry @LiottaLab, recognized as one of the premier discoverers of novel therapeutics in the U.S., is presenting a talk titled “Novel Therapeutics for Treating Cancers, Neurological Disorders & Viral Diseases” on 10/28. https://t.co/ZDth4w7MOY
From Liotta group member Dr. Luke Hodson - “I had such a great time showcasing Agrithera’s cannabinoid prodrug technology at the #cghisummit on Tuesday. Special congrats to Dr. Dennis Liotta, for being awarded runner up in the pitch rounds!” Congratulations @EricJMillerLab @gjfCD